



**ASX & MEDIA RELEASE
29 MARCH, 2012**

MARSHALL EDWARDS CEO TO PRESENT AT NEEDHAM HEALTHCARE CONFERENCE

Novogen Limited's subsidiary, Marshall Edwards, Inc., (NASDAQ: MSHL) has made the following announcement:

San Diego – 28 March, 2012 – Marshall Edwards, Inc., an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today that Daniel P Gold, PhD, President and Chief Executive Officer, will present an update on Marshall Edwards and the clinical development of its lead oncology drug candidates, ME-143 and ME-344, at the Needham Healthcare Conference on Wednesday, 4 April, 2012 at 8.40am US Eastern time from the New York Palace Hotel. A live webcast of the presentation can be accessed at www.marshalledwardsinc.com/investor. A replay will be available approximately one hour after the presentation.

About Marshall Edwards

Marshall Edwards, Inc. is a San Diego-based oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism. The company's lead drug candidates, ME-143 and ME-344, have been shown to interact with specific enzyme targets resulting in inhibition of tumour cell metabolism, a function critical for cancer cell survival. Marshall Edwards initiated a Phase I clinical trial of intravenous ME-143 in patients with solid refractory tumours in September, 2011 and expects to collect final safety and pharmacokinetic data from the trial by June, 2012. The company submitted an Investigational New Drug application for ME-344 in March, 2012 and plans to initiate a Phase I clinical trial of intravenous ME-344 in patients with solid refractory tumours following approval by the FDA. For more information, please visit www.marshalledwardsinc.com.

About Novogen Limited

Novogen Limited (ASX: NRT NASDAQ:NVGN) is an Australian biotechnology company based in Sydney, Australia. Novogen conducts research and development on oncology therapeutics through its subsidiary, Marshall Edwards, Inc., and is developing glucan technology through its subsidiary, Glycotex, Inc. More information on the Novogen group of companies can be found at www.novogen.com.

ISSUED FOR	:	NOVOGEN LIMITED
LISTINGS	:	ASX (CODE NRT), NASDAQ (CODE NVGN).
FOR FURTHER INFORMATION :	:	PETE DE SPAIN, SR DIRECTOR IR AND CORPORATE COMMUNICATIONS, MARSHALL EDWARDS, INC. TEL +1 858-792-3729 http://www.marshalledwardsinc.com
ISSUED BY CONTACT	:	WESTBROOK COMMUNICATIONS IAN WESTBROOK TEL (02) 9231 0922